AllDocs -> cancers

Page 1 of 3 of Instrument No.35 of 1994 Instrument No.35 of 1994 REVOKED Statement of Principles concerning ACUTE MYELOID LEUKAEMIA ICD CODE: 205.0 Veterans’ Entitlements Act 1986 subsection 196B(2) 1. Being of the view that there is sound medical-scientific evidence that indicates that acute myeloid leukaemia and death from acute myeloid leukaemia can be related to operational service rendered by veterans, peacekeeping service rendered by members of Peacekeeping forces and hazardous service rendered by members of the Forces, the Repatriation Medical Authority hereby determines, under subsection 196B(2) of the Veterans' Entitlements Act 1986 , that the factors that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting acute myeloid leukaemia or death from acute myeloid leukaemia ...

Page 1 of 3 of Instrument No.77 of 1995 Instrument No.77 of 1995 Statement of Principles concerning ACUTE LYMPHOID LEUKAEMIA ICD CODE: 204.0 Veterans’ Entitlements Act 1986 subsection 196 B (2) 1. Being of the view that there is sound medical-scientific evidence that indicates that acute lymphoid leukaemia and death from acute lymphoid leukaemia can be related to operational service rendered by veterans, peacekeeping service rendered by members of Peacekeeping forces and hazardous service rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(2) of the Veterans’ Entitlements Act 1986 , that the factors that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting acute lymphoid leukaemia or death from acute lymphoid leukaemia ...

Page 1 of 3 of Instrument No.78 of 1995 Instrument No.78 of 1995 Statement of Principles concerning ACUTE LYMPHOID LEUKAEMIA ICD CODE: 204.0 Veterans’ Entitlements Act 1986 subsection 196B(3) 1. Being of the view that, on the sound medical-scientific evidence available to the Repatriation Medical Authority, it is more probable than not that acute lymphoid leukaemia and death from acute lymphoid leukaemia can be related to eligible war service (other than operational service) rendered by veterans and defence service (other than hazardous service) rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(3) of the Veterans’ Entitlements Act 1986 , that the factors that must exist before it can be said that, on the balance of probabilities, acute lymphoid leukaemia or death from acute lymphoid ...

Page 1 of 2 of Instrument No.36 of 1994 Instrument No.36 of 1994 REVOKED Statement of Principles concerning ACUTE MYELOID LEUKAEMIA ICD CODE: 205.0 Veterans’ Entitlements Act 1986 subsection 196B(3) 1. Being of the view that, on the sound medical-scientific evidence available to the Repatriation Medical Authority, it is more probable than not that acute myeloid leukaemia and death from acute myeloid leukaemia can be related to eligible war service (other than operational service) rendered by veterans and defence service (other than hazardous service) rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(3) of the Veterans’ Entitlements Act 1986 , that the factors that must exist before it can be said that, on the balance of probabilities, acute myeloid leukaemia or death from acute ...

Page 1 of 2 of Instrument No.99 of 1995 Instrument No.99 of 1995 REVOKED Statement of Principles concerning CHRONIC MYELOID LEUKAEMIA ICD CODE: 205.1 Veterans’ Entitlements Act 1986 subsection 196 B (2) 1. Being of the view that there is sound medical-scientific evidence that indicates that chronic myeloid leukaemia and death from chronic myeloid leukaemia can be related to operational service rendered by veterans, peacekeeping service rendered by members of Peacekeeping forces and hazardous service rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(2) of the Veterans’ Entitlements Act 1986 , that the factors that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting chronic myeloid leukaemia or death from chronic ...

Page 1 of 2 of Instrument No.80 of 1995 Instrument No.80 of 1995 Statement of Principles concerning CHRONIC LYMPHOID LEUKAEMIA ICD CODE: 204.1 Veterans’ Entitlements Act 1986 subsection 196B(3) 1. Being of the view that, on the sound medical-scientific evidence available to the Repatriation Medical Authority, it is more probable than not that chronic lymphoid leukaemia and death from chronic lymphoid leukaemia can be related to eligible war service (other than operational service) rendered by veterans and defence service (other than hazardous service) rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(3) of the Veterans’ Entitlements Act 1986 , that the factors that must exist before it can be said that, on the balance of probabilities, chronic lymphoid leukaemia or death from chronic ...

Page 1 of 2 of Instrument No.100 of 1995 Instrument No.100 of 1995 REVOKED Statement of Principles concerning CHRONIC MYELOID LEUKAEMIA ICD CODE: 205.1 Veterans’ Entitlements Act 1986 subsection 196B(3) 1. Being of the view that, on the sound medical-scientific evidence available to the Repatriation Medical Authority, it is more probable than not that chronic myeloid leukaemia and death from chronic myeloid leukaemia can be related to eligible war service (other than operational service) rendered by veterans and defence service (other than hazardous service) rendered by members of the Forces, the Repatriation Medical Authority determines, under subsection 196B(3) of the Veterans’ Entitlements Act 1986 , that the factor that must exist before it can be said that, on the balance of probabilities, chronic myeloid leukaemia or death ...

Page 1 of 2 of Instrument No.148 of 1996 Instrument No.148 of 1996 REVOKED Amendment of Statement of Principles concerning CHRONIC MYELOID LEUKAEMIA ICD CODE: 205.1 Veterans’ Entitlements Act 1986 subsection 196B(3) The Repatriation Medical Authority amends, under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act), Instrument No.100 of 1995, (Statement of Principles concerning chronic myeloid leukaemia ) by: 1. omitting paragraph 1(d), and replacing it with the following: “(a) smoking 35 pack years of cigarettes before the clinical onset of chronic myeloid leukaemia and, where smoking has ceased, the clinical onset of chronic myeloid leukaemia has occurred within five years of cessation; (b) inability to obtain appropriate clinical management for chronic myeloid leukaemia .”; 2. omitting paragraph 2 and ...

Page 1 of 2 of Instrument No.120 of 1996 Instrument No.120 of 1996 REVOKED Amendment of Statement of Principles concerning ACUTE MYELOID LEUKAEMIA ICD CODE: 205.0 Veterans’ Entitlements Act 1986 The Repatriation Medical Authority amends, under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act), Instrument No.36 of 1994, (Statement of Principles concerning acute myeloid leukaemia , as amended by Instrument No.270 of 1995) by: 1. inserting, immediately after paragraph 1(bb) the following: “(bc) smoking cigarettes or other tobacco products equivalent to at least 15 pack years before the clinical onset of acute myeloid leukaemia , and, where smoking has ceased, the clinical onset of acute myeloid leukaemia has occurred within five years of cessation;”; 2. inserting in paragraph 4 after the definition ...

Page 1 of 2 of Instrument No.119 of 1996 Instrument No.119 of 1996 REVOKED Amendment of Statement of Principles concerning ACUTE MYELOID LEUKAEMIA ICD CODE: 205.0 Veterans’ Entitlements Act 1986 The Repatriation Medical Authority amends, under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act), Instrument No.35 of 1994, (Statement of Principles concerning acute myeloid leukaemia , as amended by Instrument No.269 of 1995) by: 1. omitting paragraph 1(c) and replacing it with the following: “(c) smoking cigarettes or other tobacco products equivalent to at least 15 pack-years before the clinical onset of acute myeloid leukaemia , and, where smoking has ceased, the clinical onset of acute myeloid leukaemia has occurred within ten years of cessation;”; 2. omitting in paragraph 4 the definition of “pack-year” ...

Introduction Haematological neoplasms are usually primarily sensitive to chemotherapy, but the relapse rate is still high, except for Hodgkin’s lymphoma and childhood acute lymphoblastic leukaemia (ALL). Drug resistance is therefore a major cause of chemotherapeutic failure and patient death in haemato-oncology. A mathematical model for the development of drug resistance in tumours was proposed in 1979 by Goldie and Coldman (1). This model was based on the postulate that cancer cells have a high spontaneous mutation rate, leading over time to the emergence of cells resistant to chemotherapeutic drugs. In accordance with this hypothesis, it was suggested that a reduction in the rate of emergence of resistant cells could be achieved by the simultaneous administration of multiple drugs with different targets. However, despite combination chemotherapies, treatment failures were observed in ...

For personal use. Only reproduce with permission from The Lancet Publishing Group. RESEARCH LETTERS 2 Nicoll A, Heath P. Neonatal group B streptococcal infection in South Bedfordshire, 1993–98. Arch Dis Child 2000; 82: F207. 3 Beardsall K. Guidelines for Group B streptococcus. Arch Dis Child Fetal Neonatal Ed 2001; 84: F77–78. 4 Ahmet Z, Stanier P, Harvey D, Holt D. New PCR primers for the sensitive detection and specific identification of Group B -hemolytic streptococci in cerebrospinal fluid. Mol Cell Probes 1999; 13: 349–57. 5 Bedford Russell AR, Breathnach A, Sender P. Confirmed group B streptococcus infection: the tip of the iceberg. Arch Dis Child Fetal Neonatal Ed 2001; 84: F140. St George’s Hospital, London, UK (S Luck MRCPCH , M Torry MRCPCH , K d’Agapeyeff MRCPCH , A Pitt MRCPCH , P T Heath ...

A nationwide case-control study of childhood leukaemia in New Zealand included measurements of electric and magnetic fields in children’s homes. There was no significant association between leukaemia and the time-weighted average of the 50 Hz magnetic or electric fields in the bedroom and living (or daytime) room combined. The controversy about whether childhood cancers are linked to electromagnetic field exposures has lasted for 20 years. Recent childhood leukaemia case-control studies have involved measurements of electromagnetic fields. 1–5 Two of these were large studies. 1,4 A nationwide New Zealand study was reported last year. 3 This communication arises from a suggestion for further analysis of the New Zealand data (personal communication from R Doll, Sept 9, 1998), to facilitate comparisons between studies. The New Zealand study was ...

SHORT REPORT Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide E RSI V OSKARIDOU , 1 E VANGELOS T ERPOS , 2 V ERONIKI K OMNINAKA , 2 E FTYHIOS E FTYHIADIS , 3 M ARINA M ANTZOURANI 2 AND D IMITRIS L OUKOPOULOS 2 1 Unit of Thalassaemia, Laikon General Hospital, 2 First Department of Medicine, University of Athens School of Medicine, and 3 Unit of Thalassaemia, Karditsa General Hospital, Greece Received 10 June 2001; accepted for publication 22 August 2001 ...

leukaemia Anti-CD33 engineered lymphocytes for the treatment of myeloid leukaemia . Dr. Peter J. Nicholls Department of Biosciences University of Kent at Canterbury Acute Myeloid Leukaemia (AML) Characterised by proliferation of myeloid cells in the bone marrow. In the USA, annual incidence of the disease is 2.4 per 100,000 people, increasing to 12.6 per 100,000 at >65 years of age. Prior to 1970, 5 year survival rates <15% Recent refinements in diagnosis/therapy have improved outlook for AML patients. Nevertheless, survival rate for patients <65 years old is just 40%. Source: NEJM 341 (14), 1051 [1999] Clinical Presentation in AML Clinical signs (e.g. fatigue, haemorrage, infection, dyspnea) are initially ...

British Journal of Haematology, 2001, 113, 439±442 SHORT REPORT Variant Philadelphia translocations in chronic myeloid leukaemia can mimic typical blast crisis chromosome abnormalities or classic t(9;22): a report of two cases Alistair Reid, 1 Susan M. Gribble, 1 Brian J. P. Huntly, 1 Kathryn M. Andrews, 2 Lynda Campbell, 3 Colin D. Grace, 4 Marion E. Wood, 5 Anthony R. Green 1 and Ellie P. Nacheva 1 1 Department of Haematology, University of Cambridge, 2 Department of Haematology, Addenbrookes Hospital, Cambridge, UK, 3 Victorian Cancer Cytogenetics Service, St. Vincents Hospital, Melbourne, Australia, 4 Digital Scientific Ltd, Cambridge, and 5 Department of Haematology, Colchester General ...

Acta Haematol 2002;107:64–75 Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia Jaspal Kaeda a Andrew Chase b John M. Goldman a a Department of Haematology, Imperial College at Hammersmith Hospital, London, b Leukaemia Research Unit, Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK Prof. John M. Goldman Department of Haematology Imperial College at Hammersmith Hospital Du Cane Road, London W12 0NN (UK) Tel. +44 20 8383 3238, E-Mail j.goldman@ic.ac.uk ABC Fax + 41 61 306 12 34 E-Mail karger@karger.ch www.karger.com © 2002 S. Karger AG, Basel 0001–5792/02/1072–0064$18.50/0 Accessible online at: www.karger.com/journals/aha Key Words Chronic myeloid leukaemia W Ph chromosome ...

July 1998, Vol. 27 No. 4 491 Infections in Acute Lymphoblastic Leukaemia —C Y Chong et al Infections in Acute Lymphoblastic Leukaemia C Y Chong,* MBBS, MRCP (UK) , A M Tan,** FAMS, MBBS, M Med (Paed) ,J Lou,** FAMS, M Med (Paed), FRCAP (Aust) Abstract We did a retrospective study of all acute lymphoblastic leukaemia (ALL) patients on United Kingdom ALL protocol who were admitted for febrile neutropenia. The aim of the study was to document the types of infections and aetiological agents associated with febrile neutropenia and to document the factors affecting mortality. Over the 8 1 / 2 -year period from 1986 to June 1995, there were 77 episodes in 32 children with a mean of 2.4 episodes. Morbidity due to infection was 61%; unknown causes of fever contributed 39%. Of the microbiologically ...

July 1998, Vol. 27 No. 4 485 Childhood Leukaemia Integrated Psychosocial Intervention Model—B Macner-Licht et al Childhood Leukaemia : Towards an Integrated Psychosocial Intervention Programme in Singapore B Macner-Licht,* MPH, MSocWk , V Rajalingam,** MBBS, M Med (Paed) , V Bernard-Opitz,*** PhD (Psych) Abstract A hospital-based behavioural intervention programme was developed for families of children with newly diagnosed or relapsed Acute Lymphoblastic Leukaemia (ALL). The programme’s aim was to enhance the families’ ability to cope with the emotionally distressing aspects of the illness and the medical treatment. Eight children and 10 parents participated in the programme for 12 weeks. The children received individual therapeutic play sessions and computer-assisted distraction activities, while the parents participated in a structured ...

July 2001, Vol. 30 No.4 401 ATRA and Chemotherapy for APL—L P Koh et al Treatment of Acute Promyelocytic Leukaemia Using a Combination of All-trans Retinoic Acid and Chemotherapy L P Koh,* MBBS, MRCP(UK) , Y T Goh,** FAMS, MBBS, M Med (Int Med) , G Teoh,*** MBBS, M Med (Int Med), Cert Rad Safety (Harvard University) , P Tan,** FAMS, MBBS, M Med (Int Med) Abstract Introduction: The combination of all-trans retinoic acid (ATRA) with chemotherapy has improved the outcome of acute promyelocytic leukaemia (APL). Effective induction as well as maintenance therapy for APL can be achieved using this combination of anti-leukaemic agents. Materials and Methods: Twenty-four consecutive patients with newly-diagnosed APL were treated with ATRA daily together with either daunorubicin or idarubicin. Therapy with ATRA was ...

November 1999, Vol. 28 No. 6 867 A Case Report of ATLL—W Y K Hwang et al A Case Report of Adult T-Cell Leukaemia /Lymphoma (ATLL) W Y K Hwang,* MBBS, MRCP (UK), M Med (Int Med) , S L Tien,** FAMS, M Med (Int Med), FRCPA , P H C Tan,*** FAMS, MBBS, M Med (Int Med) Abstract Adult T-cell leukaemia /lymphoma (ATLL) is a unique disease with distinct manifestations, a characteristic phenotype and a likely retroviral aetiology. It is unusual in Southeast Asia, though more commonly seen in some countries like Japan. We report a case of this disease in a 71-year-old man in Singapore who presented with papular erythematous eruptions for 6 years and subsequently developed generalised lymphadenopathy. He was diagnosed to have ATLL and, despite an initial response, became resistant to combination chemotherapy. We discuss the aetiology, characteristics ...

Article Abstract Online ISSN: 1097-0215 Print ISSN: 0020-7136 International Journal of Cancer Volume 65, Issue 5, 1996. Pages: 584-590 Published Online: 6 Dec 1998 Copyright © 1996 Wiley-Liss, Inc. Human Cancer Sero-epidemiological analysis of the risk of virus infections for childhood leukaemia Brigitte Schlehofer 1 * , Maria Blettner 1 , Karsten Geletneky 1 , Hans-Günter Haaf 2 , Peter Kaatsch 2 , Jörg Michaelis 2 , Nikolaus Mueller-Lantzsch 3 , Dorothea Niehoff 1 , Bernd Winkelspecht 3 , Jürgen Wahrendorf 1 , Jörg R. Schlehofer 1 4 1 Divisions of Epidemiology and Applied Tumour Virology, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg 2 ...

102 23 Leukaemia Summary Relative survival after diagnosis of leukaemia is poor when compared with relative survival of other cancer sites. Relative survival one year after diagnosis of leukaemia was 65.7% for males and 62.9% for females. Five-year relative survival was 41.2% for males and 43.2% for females (Table 23.1). Survival ten years after diagnosis was 34.1% for males and 35.9% for females in 1987–1991, the most recent period for which ten-year relative survival data are available (Figure 23.2; Tables 23.2 and 23.3). There was no significant difference in relative survival for males between 1982–1986 and 1992–1997. For females, there was an increase in five-, six- and seven-year relative survival, with relative survival five years after diagnosis increasing by 3.8 percentage points (Figure 23.2; Tables 23.2 and 23.3). Leukaemia affects a larger proportion of children than older age ...

Study Title: AML 14: A study Conducted by the MRC Adult Leukaemia Working Party Sponsored by the Leukaemia Research Fund. Information Sheet. Title of Project: Sample Donation to Research You have recently agreed to enter a clinical trial devised by the MRC Adult Leukaemia Working Party. You have been given an Information Sheet about this trial and signed a separate consent form. You are now being asked to consent to some of your bone marrow and/or blood samples being stored to be used for further research. You are not being asked to have extra samples taken, but for some of the sample from your diagnostic and monitoring tests to be stored after the tests have been done. Background Acute leukaemia is a form of cancer of the primitive cells that would normally make the blood cells or cells of the lymphoid system. Leukaemia (and other forms of cancer) are caused by ...

Department of Medicine National University Hospital Lower Kent Ridge Road Singapore 119074 S M Khoo, MBBS, MRCP (U.K.) Registrar K H Lee, MBBChir, MRCP, FAMS Associate Professor M Notley Registered Respiratory Therapist Correspondence to: K H Lee Fax: (65) 6772 4361 Email: mdcleekh@ nus.edu.sg ABSTRACT Rapid consumption of oxygen by leucocytes can result in erroneous diagnosis of severe hypoxaemia in patients with extreme leucocytosis. We report a case of chronic myeloid leukaemia , extreme leucocytosis and arterial hypoxaemia which was out of proportion to the clinical and radiological evidence of lung disease. The pseudohypoxaemia was confirmed by pulse oximeter and became less significant after successful reduction of leucocyte counts following leucophoresis and chemotherapy. ...

Computerised advice on drug dosage decisions in childhood leukaemia : a method and a safety strategy C. Hurt 1 , J. Fox 1 , J.Bury 2 , V. Saha 3 1 Advanced Computation Laboratory, Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK chris.hurt@cancer.org.uk; john.fox@cancer.org.uk 2 Academic Unit of Pathology, University of Sheffield Medical School, Sheffield S10 2UL, UK j.p.bury@sheffield.ac.uk 3 Children’s Cancer Group, Cancer Research UK, Dept of Paediatric Haematology and Oncology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Stepney Way, London E1 1BB, UK vaskar.saha@cancer.org.uk Abstract. Currently over 95% of children who are diagnosed with Acute Lym- phoblastic Leukaemia in the UK are enrolled into Medical ...

NEUROTOXICITY IN CHILDREN AFTER TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKAEMIA AND METHOTREXATE NEUROTOXICITY IN A CONTROLLED ANIMAL MODEL SATU LEHTINEN Department of Paediatrics, University of Oulu OULU 2003 Page 2 Page 3 SATU LEHTINEN NEUROTOXICITY IN CHILDREN AFTER TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKAEMIA AND METHOTREXATE NEUROTOXICITY IN A CONTROLLED ANIMAL MODEL Academic Dissertation to be presented with the assent of the Faculty of Medicine, University of Oulu, for public discussion in the Auditorium of the Department of Paediatrics, on June 13th, 2003, at 12 noon. OULUN YLIOPISTO, OULU 2003 Page 4 Copyright © 2003 University of Oulu, 2003 Supervised by Docent Marjatta Lanning ...

www.verdinrete.it/ondakiller British Journal of Cancer (2000) 83 (5), 692-698 Received 23 May 2000 Revised 16 June 2000 Accepted 16 June 2000 Correspondence to: A Ahlbom A pooled analysis of magnetic fields and childhood leukaemia A Ahlbom 1 , N Day 2 , M Feychting 1 , E Roman 3 , J Skinner 2 , J Dockerty 4 , M Linet 5 , M McBride 6 , J Michaelis 7 , JH Olsen 8 , T Tynes 9 and PK VerkasaIo 10,11,12 1 Division of Epidemiology, National Institute of Environmental Medicine, Karolinska Insitute Sweden; 2 Strangeways Research Laboratory University of Cambridge, UK; 3 Leukaemia Research Fund Centre for Clinical Epidemiology, ...

Abstract Leukaemia inhibitory factor (LIF) has been re- ported to specifically enhance myoblast proliferation in vitro and increase the number and size of myotubes in regenerating skeletal muscle in vivo. The present study specifically tests the effect of LIF on myoblast replica- tion in vivo. Administration of exogenous LIF by slow release alginate gels in vivo sustained the level of myo- blast proliferation at 2 days in regenerating crush-injured muscle. Since the extracellular matrix (ECM) plays an important role in regulating the effects of many growth factors, the hypothesis was tested, both in vivo and in vitro, that some of the beneficial effects of LIF are medi- ated by modulation of the ECM. The effects of LIF in vi- vo on the amount and localisation of the ECM mole- cules, fibronectin, tenascin-C, collagen type IV and lam- inin were assessed by immunohistochemistry on regener- ating ...